Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183153 | 0.89 | L3MBTL1 (0.48) | ALDH1A1KDM4EGLAGAAMAPK1 | |
| SCHEMBL16028248 | 0.88 | SMN1; SMN2 (0.54) | ALDH1A1KDM4EGAAMAPK1HPGD | |
| SCHEMBL1753091 | 0.86 | SMN1; SMN2 (0.53) | TP53ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL14611252 | 0.85 | MEN1 (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13206624 | 0.85 | MEN1 (0.49) | ALDH1A1KMT2AL3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL7987441 | 0.85 | MEN1 (0.49) | ALDH1A1GAAKMT2AL3MBTL1MEN1 | |
| SCHEMBL12429215 | 0.83 | TP53 (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8059093 | 0.80 | HTT (0.54) | TP53ALDH1A1KDM4EMAPK1HPGD | |
| SCHEMBL28567653 | 0.79 | LMNA (0.45) | TP53ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL12429208 | 0.78 | TP53 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| WO-2011100838-A1 | DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| EP-1912991-B1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7786301-B2 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100099690-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20100099690-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-7312223-B2 | 8-Amino-7-phenylmethyl-1-ethyl-3,7-dihydro-3-(2-hydroxyethyl)-purine-2,6-dione derivatives; urogenital, respiratory system, kidney, cardiovascular, autoimmune or brain disorders; angina pectoris, hypertension, restenosis; anticarcinogenic, hypoglycemic, antiischemic, and hypotensive agents; diabetes | SCHERING CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312223-B2 | 8-Amino-7-phenylmethyl-1-ethyl-3,7-dihydro-3-(2-hydroxyethyl)-purine-2,6-dione derivatives; urogenital, respiratory system, kidney, cardiovascular, autoimmune or brain disorders; angina pectoris, hypertension, restenosis; anticarcinogenic, hypoglycemic, antiischemic, and hypotensive agents; diabetes | SCHERING CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7192962-B2 | Xanthine phosphodiesterase V inhibitor polymorphs | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192962-B2 | Xanthine phosphodiesterase V inhibitor polymorphs | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017261-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2003101992-A1 | PROCESS FOR PREPARING XANTHINE PHOSPHODIESTERASE V INHIBITORS AND PRECURSORS THEREOF | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101991-A1 | XANTHINE PHOSPHODIESTERASE V INHIBITOR POLYMORPHS | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | MED1, ZC3HAV1, BET1 | TUBB4A 1480/4885TUBB 966/4885TUBA3C 2394/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | TUBB4A 4650/4885TUBB 4827/4885TUBA3C 4850/4885 |
| US-20100099690-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, HCAR1 | TUBB4A 4653/4885TUBB 4831/4885TUBA3C 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.